ArriVent BioPharma, Inc. Common Stock Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2022
-44M
-37M
0M
0M
0M
-7M
0M
0M
170M
0M
-0 %
0M
0M
0M
163M
126M
37M
-44M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
3Q2023
4Q2022
-15M
-14M
0M
0M
0M
-1M
0M
0M
-1M
0M
-0 %
0M
0M
0M
141M
-16M
158M
-15M
-16M
-10M
0M
0M
0M
-6M
0M
0M
110M
0M
-0 %
0M
0M
0M
163M
94M
70M
-16M